Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family protients

Molecular Cancer Therapeutics

Volumn 5, Issue 5, 2006, Pages 1335-1341

  Aziz, Moammir H ^a   Nihal, Minakshi ^a   Fu, Vivian X ^b   Jarrard, David F ^b   Ahmad, Nihal ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRIBOLONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN KINASE B; RESVERATROL;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN LNCAP; CELL SURVIVAL; CELL VIABILITY; CHEMOPROPHYLAXIS; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROGENS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STILBENES;

EID: 33745089904     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0526     Document Type: Article

References (38)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Aziz MH, Kumar R, Ahmad N. Cancer chernoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol 2003;23:17-28.
3. Gupta S, Ahmad N, Mukhtar H. Prostate cancer chemoprevention by green tea. Semin Urol Oncol 1999;17:70-6.
4. Bianchini F, Vainio H. Wine and resveratrol: mechanisms of cancer prevention? Eur J Cancer Prev 2003;12:417-25.
5. Savouret JF, Quesne M. Resveratrol and cancer: a review. Biomed Pharmacother 2002;56:84-87.
6. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004; 24:2783-40.
7. Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann N Y Aced Sci 2002;957:210-29.
8. Bhat KPL, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal 2001;3:1041-64.
9. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275: 218-20.
10. Goldberg DM, Hahn SE, Parkes JG. Beyond alcohol: beverage consumption and cardiovascular mortality. Clin Chim Acta 1995;237: 155-87.
11. Jones SB, DePrimo SE, Whitfield ML, et al. Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2005;14:596-604.
12. Kim YA, Rhee SH, Park KY, et al. Antiproliferative effect of resveratrol in human prostate carcinoma cells. J Med Food 2003;6:273-80.
13. Narayanan BA, Narayanan NK, Re GG, et al. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer 2003;104:204-12.
14. Kampa M, Hatzoglou A, Notas G, et al. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 2000;37:223-33.
15. Hsieh TC, Wu JM. Differential effects on growth, cell cycle arrest and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 1999;249:109-15.
16. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004;9:667-76.
17. Wetzker R, Rommel C. Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr Pharm Des 2004;10:1915-22.
18. Fresno Vara JA, Casado E, de CJ, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204.
19. Franke TF, Hornik CP, Segev L, et al. PI3K/Akt and apoptosis: size matters. Oncogene 2003;22:8983-98.
20. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62.
21. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 2002;277:30935-41.
22. Pfeil K, Eder IE, Putz T, et al. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 2004;58:259-68.
23. Ghosh PM, Malik S, Bedolla R, et al. Akt in prostate cancer: possible role in androgen-independence. Curr Drug Metab 2003;4:487-96.
24. Murillo H, Huang H, Schmidt LJ, et al. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142:4795-805.
25. Kumar P, Miller AI, Polverini PJ. p38 MAPK mediates γ-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem 2004;279:43352-60.
26. Asnaghi L, Calastretti A, Bevilacqua A, et al. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 2004;23:5781-91.
27. Jin YP, Fishbein MC, Said JW, et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004;65: 291-302.
28. Schwarze SR, Shi Y, Fu VX, et al. Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 2001;20:8184-92.
29. Jarrard DF, Sarkar S, Shi Y, et al. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res 1999;59:2957-64.
30. Garikapaty VP, Ashok BT, Tadi K, et al. Synthetic dimer of indole-3-carbinol: second generation diet derived anti-cancer agent in hormone sensitive prostate cancer. Prostate 2006;66:453-62.
31. Sgambato A, Ardito R, Faraglia B, et al. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res 2001;496:171-80.
32. Bove K, Lincoln DW, Tsan MF. Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun 2002; 291:1001-5.
33. Fukuhara K, Nagakawa M, Nakanishi I, et al. Structural basis for DNA-cleaving activity of resveratrol in the presence of Cu(II). Bioorg Mad Chem 2006;14:1437-43.
34. Tyagi A, Singh RP, Agarwal C, et al. Resveratrol causes Cdc2-15 phosphorylation via ATM/ATR-Chkl/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 2005;26:1978-87.
35. Li L, Ittmann MM, Ayala G, et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005;8:108-18.
36. Shukla S, Maclennan GT, Marengo SR, et al. Constitutive activation of PI3K-Akt and NF-ΚB during prostate cancer progression in autochtho-nous transgenic mouse model. Prostate 2005;64:224-39.
37. Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64:5232-6.
38. Pommery N, Henichart JP. Involvement of PI3K/Akt pathway in prostate cancer. Potential strategies for developing targeted therapies. Ann Pharm Fr 2005;63:69-75.